AREXVY recommended for adults aged 50-59 at increased risk for severe respiratory syncytial virus (RSV) disease by US Advisory Committee on Immunization Practices
GlaxoSmithKline PLC (GSK)
US:NYSE Investor Relations:
gsk.com/en-gb/investors
Company Research
Source: Business Wire
Over 13 million adults aged 50-59 at increased risk in the US can potentially benefit from RSV immunization1RSV causes an estimated 42,000 hospitalizations* each year in adults aged 50-64 years old in the US2 PHILADELPHIA--(BUSINESS WIRE)--GSK plc (LSE/NYSE: GSK) is pleased that the Advisory Committee on Immunization Practices (ACIP) voted in favor of recommending the use of RSV vaccines including GSK’s AREXVY (Respiratory Syncytial Virus Vaccine, Adjuvanted) in adults aged 50-59 who are at increased risk for severe RSV disease. This includes people with conditions like COPD, asthma, diabetes, heart disease and those in residential care3. This expands on ACIP’s previous vote in June 2024 to recommend RSV vaccines for adults aged 60-74 who are at increased risk and all adults aged 75 and older. AREXVY is indicated for the prevention of lower respiratory tract disease (LRTD) caused by RSV in individuals 60 years of age and older, as well as individuals 50 through 59 years of age who
Show less
Read more
Impact Snapshot
Event Time:
GSK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GSK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GSK alerts
High impacting GlaxoSmithKline PLC news events
Weekly update
A roundup of the hottest topics
GSK
News
- Samsung Biologics Expands U.S. Manufacturing Capabilities with Strategic Acquisition of Human Genome Sciences from GSKPR Newswire
- Exdensur (depemokimab) approved by US FDA for the treatment of severe asthmaBusiness Wire
- GSK (GSK) Scores Win in the Form of Lung Cancer Drug's Orphan Drug Designation [Yahoo! Finance]Yahoo! Finance
- GSK (NYSE:GSK) had its "reduce" rating reaffirmed by analysts at HSBC Holdings plc.MarketBeat
- GSK (NYSE:GSK) had its "buy (b)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
GSK
Sec Filings
- 12/22/25 - Form 6-K
- 12/22/25 - Form 6-K
- 12/19/25 - Form 6-K
- GSK's page on the SEC website